Investigational drug · Phase 3
SHR-A1904
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Biliary Tract Cancer, Advanced Solid Tumors.
Phase 3Last checked: Nov 19, 2026Latest source record: May 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
13
Any phase or sponsor naming "SHR-A1904"
First trial start
2022
May 30, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SHR-A1904", any sponsor or status.
Conditions studied
As listed on its trial records.
- Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- Biliary Tract Cancer
- Advanced Solid Tumors
- Gastric Cancer
- Gastroesophageal-junction Cancer
- Advanced Gastric Cancer
- Metastatic Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
Approved drugs for the same conditions: Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "SHR-A1904" as an intervention, largest first.
Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
NCT06350006 · 924 participants (planned) · Start May 29, 2024 · Primary completion Dec 30, 2027
Drug: SHR-A1904; Adebrelimab; SHR-A1904; CAPOX; Adebrelimab · For: CLDN18.2-positive Advanced Solid Tumor
Sites: Guangzhou, China
- SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaPivotal-lookingRecruiting
Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
NCT06649292 · 524 participants (planned) · Start Nov 22, 2024 · Primary completion Sep 20, 2027
Drug: SHR-A1904; Paclitaxel, Docetaxel, Irinotecan · For: Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Sites: Guangzhou, China
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT07102901 · 351 participants (planned) · Start Sep 5, 2025 · Primary completion Dec 2027
Drug: SHR2554 Tablets; SHR-A1811 Injection and 2 more · For: Advanced Gastric Cancer; Metastatic Gastric Cancer; Gastroesophageal Junction Adenocarcinoma
Sites: Harbin, China; Zhengzhou, China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT07110571 · 200 participants (planned) · Start Aug 28, 2025 · Primary completion Aug 2026
Drug: Adebrelimab Injection; SHR-A1811 for Injection and 2 more · For: Gastric Cancer; Gastroesophageal-junction Cancer
Sites: Shijiazhuang, China; Hangzhou, China
Fudan UniversityAcademic, hospital or other
NCT06547736 · 160 participants (planned) · Start Oct 14, 2024 · Primary completion Mar 2027
Drug: SHR-A2102 or/and HRS-4642; SHR-A1904 or/and HRS-4642 and 2 more · For: Pancreatic Cancer
Sites: Shanghai, China
- A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract CancerPivotal-lookingRecruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT07450976 · 151 participants (planned) · Start Mar 25, 2026 · Primary completion Dec 2030
Drug: SHR-A1904 for Injection · For: Biliary Tract Cancer
Sites: Beijing, China; Shanghai, China
- Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular SubtypingNot yet recruiting
China Medical University, ChinaAcademic, hospital or other
NCT06881017 · 140 participants (planned) · Start May 1, 2025 · Primary completion Aug 1, 2029
Drug: Trastuzumab; Adebrelimab and 8 more · For: Gastric Cancer; HER2 + Gastric Cancer; CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction and 1 more
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06520488 · 118 participants (planned) · Start Aug 9, 2024 · Primary completion Mar 2027
Drug: HRS-4642 · For: Advanced Solid Tumors
Sites: Shanghai, China
- A Study of SHR-A1904 in Patients With Advanced Solid CancerActive, not recruiting
Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
NCT04877717 · 107 participants · Start Jul 1, 2021 · Primary completion Dec 1, 2025
Drug: SHR-A1904 · For: Advanced Solid Cancer
Sites: Guangzhou, China
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05277168 · 83 participants (planned) · Start May 30, 2022 · Primary completion May 2026
Drug: SHR-A1904 · For: Advanced Solid Tumors
Sites: Miami Beach, Florida; St. Petersburg, Florida; New Orleans, Louisiana · 28 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial.
Ruan DY, Wu HX, Luo SX, et al. · Nat Med 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.